Nature Communications
August 3, 2026
Frederik Gudmundsen, Julia Czurylo, Daniel Ryskamp Rijsketic et al.
Serotonergic psychedelics show therapeutic potential across neuropsychiatric disorders despite transient acute effects. These compounds share serotonin 2 A receptor agonism but differ in broader pharmacology, motivating a systematic comparison of their neurobiological effects. Here, we use [18 F]FDG-PET in rats to assess acute and one-week effects of psilocybin, LSD, and 2C-B on brain metabolic...
May 28, 2024
Frederik Gudmundsen, Julia Czurylo, Camilla Trang Vo et al.
1 citation
preprint
Serotonergic psychedelic drugs have shown promising benefits in trials for various neuropsychiatric disorders. While the acute effects of these psychedelics last only a few hours, the positive therapeutic effects can persist long after a single administration. Serotonergic psychedelics produce their psychedelic effects by activating serotonin 2A receptors, but they differ in other...
Molecular Psychiatry
September 1, 2023
Kat F. Kiilerich, Joe Lorenz, Malthe B. Scharff et al.
48 citations
Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorders. A less explored topic concerns the use of repeated low doses of psychedelics, at a dose that is well below the psychedelic dose used in psychedelic-assisted therapy and often referred to as microdosing. Psilocybin microdose users frequently report...
January 4, 2023
Klemens Egger, Frederik Gudmundsen, Naja Støckel Jessen et al.
preprint
RationaleThe psychedelic effects of the traditional Amazonian botanical decoction known as ayahuasca are attributed to the effects of N,N-dimethyltryptamine (DMT) at brain serotonin 5-HT2A receptors. To make oral DMT bioavailable, ayahuasca additionally contains reversible monoamine oxidase A (MAO-A) inhibitors, namely β-carboline alkaloids such as harmine. However, there is lacking biochemical...
Frontiers in Pharmacology
2023
Klemens Egger, Frederik Gudmundsen, Naja Støckel Jessen et al.
17 citations
Rationale: The psychedelic effects of the traditional Amazonian botanical decoction known as ayahuasca are often attributed to agonism at brain serotonin 5-HT2A receptors by N,N-dimethyltryptamine (DMT). To reduce first pass metabolism of oral DMT, ayahuasca preparations additionally contain reversible monoamine oxidase A (MAO-A) inhibitors, namely β-carboline alkaloids such as harmine....
ACS Chemical Neuroscience
May 15, 2018
Elina Tampio L’Estrade, Hanne Demant Hansen, Maria Erlandsson et al.
14 citations
High Resolution Image Download MS PowerPoint Slide Already in 1953, Woolley and Shaw speculated that serotonin could be involved in a range of central nervous system (CNS) disorders. Lysergic acid diethylamide (LSD) displayed an important role in this respect. It was used not only to antagonize biological effects of serotonin and to study the system itself, but also to identify serotonergic...